

CONTENTS

NOTE TO THE READER.....	1
LIST OF PARTICIPANTS.....	3
PREAMBLE	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review	11
4. Data for the <i>Monographs</i>	12
5. Meeting participants	12
6. Working procedures.....	13
B. SCIENTIFIC REVIEW AND EVALUATION	14
1. Exposure data.....	15
2. Studies of cancer in humans.....	16
3. Studies of cancer in experimental animals.....	20
4. Mechanistic and other relevant data.....	23
5. Summary	26
6. Evaluation and rationale.....	27
References.....	31
GENERAL REMARKS.....	33
PERFLUOROOCCTANOIC ACID	37
1. Exposure Data.....	37
1.1 Identification of the agent	37
1.2 Production and use.....	39
1.3 Occurrence and exposure.....	41
1.4 Regulations and guidelines	49

2. Cancer in Humans	49
2.1 Occupational exposure	49
2.2 Community studies of high exposure	54
2.3 Studies in the general population	60
3. Cancer in Experimental Animals	63
3.1 Rat	63
3.2 Rainbow trout	66
4. Mechanistic and Other Relevant Data	68
4.1 Toxicokinetic data	68
4.2 Genotoxicity and related effects	77
4.3 Other mechanistic data relevant to carcinogenesis	80
4.4 Organ toxicity	90
4.5 Susceptible populations	93
4.6 Mechanistic considerations	94
5. Summary of Data Reported	95
5.1 Exposure data	95
5.2 Human carcinogenicity data	96
5.3 Animal carcinogenicity data	97
5.4 Mechanistic and other relevant data	97
6. Evaluation	97
6.1 Cancer in humans	97
6.2 Cancer in experimental animals	97
6.3 Overall evaluation	98
References	98
TETRAFLUOROETHYLENE	111
1. Exposure Data	111
1.1 Identification of the agent	111
1.2 Production and use	112
1.3 Occurrence and exposure	113
1.4 Regulations and guidelines	115
2. Cancer in Humans	116
2.1 Cohort studies	116
2.2 Case-control studies	118
3. Cancer in Experimental Animals	118
3.1 Mouse	118
3.2 Rat	121
4. Mechanistic and Other Relevant Data	124
4.1 Toxicokinetic data	124
4.2 Genotoxicity and related effects	130
4.3 Biochemical and cellular effects	131
4.4 Organ toxicity	131
4.5 Susceptible populations	133
4.6 Mechanistic considerations	134

5. Summary of Data Reported	135
5.1 Exposure data	135
5.2 Human carcinogenicity data	135
5.3 Animal carcinogenicity data	136
5.4 Mechanistic and other relevant data	136
6. Evaluation	137
6.1 Cancer in Humans	137
6.2 Cancer in experimental animals	137
6.3 Overall evaluation	137
6.4 Rationale	137
References	137
1,2-DICHLOROPROPANE	141
1. Exposure Data	141
1.1 Identification of the agent	141
1.2 Production and use	142
1.3 Occurrence and exposure	143
1.4 Regulations and guidelines	145
2. Cancer in Humans	146
2.1 Cholangiocarcinoma among printing workers in Japan	146
2.2 Cholangiocarcinoma among printing workers outside Japan	152
3. Cancer in Experimental Animals	152
3.1 Mouse	152
3.2 Rat	155
4. Mechanistic and Other Relevant Data	156
4.1 Toxicokinetic data	156
4.2 Genetic and related effects	161
4.3 Biochemical and cellular effects	162
4.4 Organ toxicity	165
4.5 Susceptible populations	168
4.6 Mechanistic considerations	168
5. Summary of Data Reported	169
5.1 Exposure data	169
5.2 Human carcinogenicity data	169
5.3 Animal carcinogenicity data	170
5.4 Mechanistic and other relevant data	170
6. Evaluation	171
6.1 Cancer in humans	171
6.2 Cancer in experimental animals	171
6.3 Overall evaluation	171
References	171

DICHLOROMETHANE	177
1. Exposure Data	177
1.1 Identification of the agent	177
1.2 Production and use	179
1.3 Occurrence and exposure	181
1.4 Regulations and guidelines	184
2. Cancer in Humans	186
2.1 Introduction	186
2.2 Occupational cohort studies of workers exposed to dichloromethane	186
2.3 Case-control studies	192
2.4 Meta-analysis	206
3. Cancer in Experimental Animals	206
3.1 Mouse	206
3.2 Rat	212
3.3 Hamster	217
4. Mechanistic and Other Relevant Data	217
4.1 Toxicokinetic data	217
4.2 Genetic and related effects	225
4.3 Other mechanistic data relevant to carcinogenicity	231
4.4 Organ toxicity	233
4.5 Susceptible populations	236
4.6 Mechanistic considerations	237
5. Summary of Data Reported	240
5.1 Exposure data	240
5.2 Human carcinogenicity data	240
5.3 Animal carcinogenicity data	241
5.4 Mechanistic and other relevant data	242
6. Evaluation	242
6.1 Cancer in Humans	242
6.2 Cancer in experimental animals	243
6.3 Overall evaluation	243
6.4 Rationale	243
References	243
1,3-PROPANE SULTONE	257
1. Exposure Data	257
1.1 Identification of the agent	257
1.2 Production and use	258
1.3 Occurrence and exposure	259
1.4 Regulations and guidelines	260
2. Cancer in Humans	260
3. Cancer in Experimental Animals	260
3.1 Mouse	260
3.2 Rat	264

4. Mechanistic and Other Relevant Data	266
4.1 Toxicokinetic data	266
4.2 Genetic and related effects.....	266
4.3 Other effects relevant to carcinogenicity	269
4.4 Mechanistic considerations.....	269
5. Summary of Data Reported	270
5.1 Exposure data.....	270
5.2 Human carcinogenicity data.....	270
5.3 Animal carcinogenicity data.....	270
5.4 Mechanistic and other relevant data.....	270
6. Evaluation.....	271
6.1 Cancer in humans.....	271
6.2 Cancer in experimental animals.....	271
6.3 Overall evaluation	271
6.4 Rationale	271
References.....	271
LIST OF ABBREVIATIONS	275

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.

